{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:39:39Z","timestamp":1787071179071,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Metastatic salivary duct carcinomas (SDC) are rare tumors and evidence-based guidelines for their treatment have not yet been established. Reports of such cases like ours could be beneficial in the decision-making in the similar clinical circumstances. Here we present the 64-year-old Caucasian man with bone pain and pancytopenia two years after local treatment of SDC, in whom a bone marrow biopsy revealed poorly differentiated carcinoma of salivary origin with nuclear androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2\/neu) positivity. Clinical response was achieved with cis-platin based cytotoxic therapy and maintenance hormonal treatment. At progression after 12 months, he was treated with anti-HER2 therapy combined with taxanes. The response lasted for 14 months. Then palliative therapy with capecitabine was introduced. With a relatively sustained quality of life, the response lasted for 15 months.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_373_22","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T12:00:53Z","timestamp":1703937653000},"page":"2048-2051","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Capecitabine is effective as palliative chemotherapy in a patient with androgen receptor and HER2 positive metastatic salivary duct carcinoma. A case report"],"prefix":"10.4103","volume":"19","author":[{"given":"Luka","family":"\u010cavka","sequence":"first","affiliation":[{"name":"Department of Oncology, University Medical Center Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Zakotnik","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Institute of Oncology Ljubljana, Zaloska ulica 2, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.oraloncology.2017.09.008","article-title":"Salivary duct carcinoma:An aggressive salivary gland malignancy with opportunities for targeted therapy","volume":"74","author":"Schmitt","year":"2017","journal-title":"Oral Oncol"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"101906","DOI":"10.1016\/j.ctrv.2019.101906","article-title":"Advances and challenges in precision medicine in salivary gland cancer","volume":"80","author":"Lassche","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hed.24107","article-title":"Salivary duct carcinoma:Treatment, outcomes, and patterns of failure","volume":"38","author":"Johnston","year":"2016","journal-title":"Head Neck"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.4103\/jcrt.JCRT_645_19","article-title":"Acinic cell carcinoma of the parotid gland with neuroendocrine differentiation","volume":"17","author":"Rath","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cncy.22288","article-title":"Salivary duct carcinoma:Updates in histology, cytology, molecular biology, and treatment","volume":"128","author":"Nakaguro","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.oraloncology.2017.02.018","article-title":"New concepts of personalized therapy in salivary gland carcinomas","volume":"68","author":"Keller","year":"2017","journal-title":"Oral Oncol"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y","article-title":"Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin","volume":"60","author":"Dreyfuss","year":"1987","journal-title":"Cancer"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/mpo.2950160309","article-title":"Preliminary experience with chemotherapy in advanced salivary gland neoplasms","volume":"16","author":"Belani","year":"1988","journal-title":"Med Pediatr Oncol"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/1097-0142(19881201)62:11<2313::AID-CNCR2820621110>3.0.CO;2-4","article-title":"Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck","volume":"62","author":"Creagan","year":"1988","journal-title":"Cancer"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","article-title":"Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients","volume":"7","author":"Licitra","year":"1996","journal-title":"Ann Oncol"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.2147\/OTT.S304900","article-title":"Androgen deprivation therapy for patients with androgen-receptor-positive metastatic salivary duct carcinoma:A case report and review of the literature","volume":"14","author":"You","year":"2021","journal-title":"Onco Targets Ther"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.oraloncology.2009.05.635","article-title":"Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/hed.24634","article-title":"Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature","volume":"39","author":"Thorpe","year":"2017","journal-title":"Head Neck"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17843286.2016.1173940","article-title":"Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane:A series of six patients","volume":"71","author":"De Block","year":"2016","journal-title":"Acta Clin Belg"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3892\/mco.2017.1226","article-title":"Salivary duct carcinoma treated with cetuximab-based targeted therapy:A case report","volume":"6","author":"Kawahara","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"R16-20241021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/0284186X.2015.1068446","article-title":"Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly","volume":"55","author":"Aaldriks","year":"2016","journal-title":"Acta Oncologica"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1758-3284-2-12","article-title":"Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine","volume":"2","author":"Sharon","year":"2010","journal-title":"Head Neck Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_373_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:42:41Z","timestamp":1787067761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_373_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_373_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"2022-02-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}